Public health impact of statin prescribing strategies based on JUPITER.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_EE2A9740026B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Public health impact of statin prescribing strategies based on JUPITER.
Périodique
Preventive medicine
Auteur(s)
Nanchen D., Pletcher M.J., Cornuz J., Marques-Vidal P.M., Paccaud F., Waeber G., Vollenweider P., Rodondi N.
ISSN
1096-0260 (Electronic)
ISSN-L
0091-7435
Statut éditorial
Publié
Date de publication
02/2011
Peer-reviewed
Oui
Volume
52
Numéro
2
Pages
159-163
Langue
anglais
Notes
Publication types: Comparative Study ; Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
To evaluate the public health impact of statin prescribing strategies based on the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin Study (JUPITER).
We studied 2268 adults aged 35-75 without cardiovascular disease in a population-based study in Switzerland in 2003-2006. We assessed the eligibility for statins according to the Adult Treatment Panel III (ATPIII) guidelines, and by adding "strict" (hs-CRP≥2.0 mg/L and LDL-cholesterol <3.4 mmol/L), and "extended" (hs-CRP≥2.0 mg/L alone) JUPITER-like criteria. We estimated the proportion of CHD deaths potentially prevented over 10 years in the Swiss population.
Fifteen percent were already taking statins, 42% were eligible by ATPIII guidelines, 53% by adding "strict," and 62% by adding "extended" criteria, with a total of 19% newly eligible. The number needed to treat with statins to avoid one CHD death over 10 years was 38 for ATPIII, 84 for "strict" and 92 for "extended" JUPITER-like criteria. ATPIII would prevent 17% of CHD deaths, compared with 20% for ATPIII+"strict" and 23% for ATPIII + "extended" criteria (+6%).
Implementing JUPITER-like strategies would make statin prescribing for primary prevention more common and less efficient than it is with current guidelines.

Mots-clé
Adult, Aged, Cardiovascular Diseases/mortality, Cardiovascular Diseases/prevention & control, Cross-Sectional Studies, Drug Utilization/statistics & numerical data, Female, Fluorobenzenes/administration & dosage, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage, Male, Middle Aged, Practice Guidelines as Topic, Primary Prevention/standards, Public Health, Pyrimidines/administration & dosage, Risk Assessment, Rosuvastatin Calcium, Sulfonamides/administration & dosage, Survival Analysis, Switzerland, Treatment Outcome
Pubmed
Web of science
Création de la notice
08/12/2010 8:39
Dernière modification de la notice
20/08/2019 16:15
Données d'usage